Protein S-specific activity assay system is not affected by direct oral anticoagulants

Kuma, Hiroyuki; Matsuda, Ryo; Nakashima, Asuna; Motoyama, Kazuna; Takazaki, Shinya; Hatae, Hinako; Jin, Xiaohui; Tsuda, Teruhisa; Tsuda, Hiroko

doi:10.1016/j.thromres.2018.06.008

Cited by 8 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). Before our study, Kuma et al reported that rivaroxaban and edoxaban prolonged PT and APTT in a drug concentration-dependent manner, whereas apixaban had no such effect in vitro experiments, and these results were similar to ours 29) . However, the study by Kuma et al differs from our study because they did not use patients' plasma samples.…”

Section: B) Xa-based Assay (Fig 5 Open Squares)supporting

confidence: 91%

Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors

Terakami

Nagaya

Hayashi

et al. 2022

JAT

View full text Add to dashboard Cite

Measurement of protein S (PS) activity in patients taking direct oral anticoagulants (DOACs) using reagents based on a clotting assay results in falsely high PS activity, thus masking inherited PS deficiency, which is most frequently seen in the Japanese population. In this study, we investigated the effect of factor Xa (FXa) inhibitors on PS activity using the reagent on the basis of the chromogenic assay, which was recently developed in Japan. Methods:The study enrolled 152 patients (82 males and 70 females; the average age: 68.5 14.0 years) receiving three FXa inhibitors (rivaroxaban, edoxaban, and apixaban). PS activity was measured using the reagents on the basis of the clotting and chromogenic assays.Results: PS activity measured by the clotting assay reagents exhibited falsely high values depending on the plasma concentrations of FXa inhibitors in patients taking either rivaroxaban or edoxaban. However, none of the three FXa inhibitors affected PS activity when measured using the chromogenic assay. Conclusion:In patients taking rivaroxaban or edoxaban, inherited PS deficiency is likely missed because the levels of PS activity measured using the reagents based on the clotting assay are falsely high. However, we report that three FXa inhibitors do not affect PS activity measured by the chromogenic assay. When measuring the levels of PS activity in patients undergoing DOACs, the principles of each reagent should be understood. Furthermore, plasma samples must be collected at the time when plasma concentrations of DOACs are lowest or the DOAC-Stop reagent should be used.and their frequency of use continues to increase yearly [1][2][3][4][5] . DOACs are classified as thrombin inhibitor (dabigatran) or factor Xa (FXa) inhibitors (rivaroxaban, edoxaban, and apixaban) based on the target of inhibition. Compared with vitamin K antagonists such as warfarin, DOACs exhibit more

show abstract

Section: B) Xa-based Assay (Fig 5 Open Squares)supporting

confidence: 91%

Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors

Terakami

Nagaya

Hayashi

et al. 2022

JAT

View full text Add to dashboard Cite

show abstract

“…The factors that affect the measurement system must also be identified. However, the protein S-specific activity was not affected by DOACs or direct thrombin inhibitors such as heparin and dabigatran, which are used clinically at blood-relevant concentrations, as reported previously [ 24 ]. The protein C activity measurement method may yield similar results, because the protein S-specific activity assay system contains the quantitative total protein S-activity assay system; a theory similar to that of our new method [ 25 ].…”

Section: Discussionsupporting

confidence: 74%

A quantitative assay system for protein C activity, the regulator of blood coagulation, based on a chromogenic method mimicking the blood coagulation cascade

Matsuda,

Someya,

Kobayashi

et al. 2023

Practical Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

“…37 APC cofactor measurements performed with the colorimetric method that excludes the effects of PS-C4BP complex dissociation have high sensitivity and specificity in PS p.K196E identification, 39 and are not affected by DOACs. 40 Free PS antigen levels and total PS antigen levels are measured with ELISA using monoclonal antibodies or latex agglutination turbidimetric immunoassay.…”

Section: Tests and Diagnosismentioning

confidence: 99%

Clinical guidance for peripartum management of patients with hereditary thrombophilia

Kobayashi

Morishita

Tsuda

et al. 2021

J of Obstet and Gynaecol

Self Cite

View full text Add to dashboard Cite

Hereditary thrombophilia is a condition in which individuals are susceptible to the formation of thrombi due to a hereditary deficiency in anticoagulant factors, antithrombin (AT), protein C (PC), or protein S (PS). Many Japanese thrombophilia patients have PS deficiency, especially PS p.K196E (also called as PS Tokushima), which is exclusive to the Japanese population, and thrombosis sometimes occurs during pregnancy. At present, no management guidelines for pregnancy and delivery in thrombophilia patients have been developed. The Study Group for Hereditary Thrombophilia, one of the research groups of blood coagulation abnormalities in the Research Program on Rare and Intractable Diseases supported with the Research Grants of the Ministry of Health, Labour and Welfare Science, has therefore developed this clinical guidance to provide healthcare workers with necessary information on safe pregnancy, parturition and neonatal management, adopting a format of responses to seven clinical questions (CQ). At the end of each answer, the corresponding Recommendation Level (A, B, C) is indicated.

show abstract

Protein S-specific activity assay system is not affected by direct oral anticoagulants

Cited by 8 publications

References 8 publications

Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors

Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors

A quantitative assay system for protein C activity, the regulator of blood coagulation, based on a chromogenic method mimicking the blood coagulation cascade

Clinical guidance for peripartum management of patients with hereditary thrombophilia

Contact Info

Product

Resources

About